Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KENT R NILSSON

Allopathic & Osteopathic Physicians Internal Medicine Clinical Cardiac Electrophysiology

NPI
1619965381
CMS profile
864607
Location
ATHENS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$42,487.90

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $35,465.35 19
Travel and Lodging $3,560.07 11
Food and Beverage $3,462.48 71

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KENT R NILSSON

NPI 1619965381 · CMS profile ID 864607

Allopathic & Osteopathic Physicians / Internal Medicine / Clinical Cardiac Electrophysiology

ATHENS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619965381?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KENT R NILSSON, NPI 1619965381, CMS profile ID 864607. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619965381?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KENT R NILSSON, NPI 1619965381, CMS profile ID 864607. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619965381?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KENT R NILSSON, NPI 1619965381, CMS profile ID 864607, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619965381?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $42,487.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–101 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $4.3001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240747602 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,419.74 35
PY2020 $11,739.29 35
PY2021 $2,227.02 53
PY2022 $72,887.63 134
PY2023 $23,381.69 81
PY2024 $40,132.28 110
PY2025 $42,487.90 101

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,575.34 38
PY2024 Principal investigator $263,620.00 14
PY2023 Principal investigator $224,238.57 30
PY2022 Principal investigator $222,582.50 50
PY2021 Principal investigator $107,152.50 26
PY2020 Principal investigator $52,561.00 12
PY2019 Principal investigator $90,318.50 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boston Scientific Corporation $100,415.00 12/12/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
RESOLVE AF No dispute reported 06/30/2026 1222320422
Principal investigator 1 Janssen Research & Development, LLC $684.00 11/19/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175206650
Principal investigator 1 Abbott Laboratories $4,929.60 11/12/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248159458
Principal investigator 1 Janssen Research & Development, LLC $1,626.00 11/07/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175205678
Principal investigator 1 Janssen Research & Development, LLC $200.00 11/05/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175207249
Principal investigator 1 Janssen Research & Development, LLC $1,502.00 10/22/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175205370
Principal investigator 1 Abbott Laboratories $2,090.00 10/07/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248158134
Principal investigator 1 iRhythm Technologies, Inc. $11,060.00 09/30/2025 Covered Recipient Teaching Hospital
Piedmont Athens Regional Medical Ce
STUDY-Piedmont Athens Resolve AF No dispute reported 06/30/2026 1244039890
Principal investigator 1 Janssen Research & Development, LLC $1,626.00 09/19/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175206726
Principal investigator 1 Abbott Laboratories $792.00 09/16/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248156670
Principal investigator 1 Janssen Research & Development, LLC $1,791.00 08/25/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175204501
Principal investigator 1 Janssen Research & Development, LLC $1,409.00 08/22/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175207310
Principal investigator 1 Abbott Laboratories $5,019.30 08/18/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248155562
Principal investigator 1 Janssen Research & Development, LLC $566.00 08/14/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175205956
Principal investigator 1 Janssen Research & Development, LLC $2,405.00 08/08/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175204554
Principal investigator 1 Boston Scientific Corporation $30,900.00 07/30/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
RESOLVE AF No dispute reported 06/30/2026 1222320438
Principal investigator 1 Abbott Laboratories $792.00 07/22/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248153242
Principal investigator 1 Janssen Research & Development, LLC $2,218.00 07/11/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175204538
Principal investigator 1 Janssen Research & Development, LLC $751.00 06/26/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175206884
Principal investigator 1 Abbott Laboratories $169.00 06/24/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248152000
Principal investigator 1 Abbott Laboratories $19,436.30 06/23/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248151954
Principal investigator 1 Janssen Research & Development, LLC $1,291.00 06/20/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175205180
Principal investigator 1 Abbott Laboratories $624.00 06/12/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248151790
Principal investigator 1 Abbott Laboratories $624.00 06/05/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248151578
Principal investigator 1 Abbott Laboratories $169.00 06/05/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248151652
Principal investigator 1 Janssen Research & Development, LLC $1,785.00 05/21/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175204676
Principal investigator 1 Janssen Research & Development, LLC $1,785.00 03/21/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175206574
Principal investigator 1 Abbott Laboratories $7,000.00 03/13/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248149258
Principal investigator 1 Abbott Laboratories $7,000.00 03/11/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248149260
Principal investigator 1 Abbott Laboratories $7,000.00 03/11/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248149262
Principal investigator 1 Abbott Laboratories $2,090.00 03/05/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248147308
Principal investigator 1 Abbott Laboratories $14,650.00 02/19/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248146714
Principal investigator 1 Abbott Laboratories $7,000.00 02/17/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248149256
Principal investigator 1 Boston Scientific Corporation $19,600.00 01/31/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
RESOLVE AF No dispute reported 06/30/2026 1222320398
Principal investigator 1 Abbott Laboratories $19.14 01/22/2025 Non-covered Recipient Entity
MPX Group
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248144898
Principal investigator 1 Janssen Research & Development, LLC $1,492.00 01/22/2025 Non-covered Recipient Entity
Piedmont Hlthcare
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175209262
Principal investigator 1 Abbott Laboratories $15.00 01/14/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248148194
Principal investigator 1 Abbott Laboratories $50.00 01/14/2025 Non-covered Recipient Entity
Piedmont Healthcare Inc
NCT06676072--A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF: No dispute reported 06/30/2026 1248148196